ChiCTR1900023846进行中（未招募）不适用
Amalgamated clinical and genetic particulars to predict recurrence patterns of primary liver cancers
上海卫健委2 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2019年6月17日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
- 试验地点
- 2
- 主要终点
- 生存率
研究概览
简要总结
- To ascertain latent risk primary liver cancers that radical surgical resection of the tumor would not be able to provide curativeness due to early intrahepatic recurrence;
- To testify whether liver transplantation improves prognosis of patients with latent risk hepatocellular carcinoma;
- To testify whether adjuvant treatment following surgical resection improves prognosis of patients with latent risk intrahepatic cholangiocarcinoma.
研究设计
- 研究类型
- 观察性研究
- 主要目的
- 队列研究
- 盲法
- None
入排标准
- 性别
- All
入选标准
- •Agree to participate;
- •Age<80 years;
- •Distinctive characteristics of hepatocellular or intrahepatic cholangiocarcinoma by imaging studies;
- •Child-Pugh class A-B;
- •BCLC stage 0-B (hepatocellular carcinoma only);
- •AJCC stage I-IIIa;
- •ECOG performance status 0-1;
- •Within Milan criteria (hepatocellular carcinoma only).
排除标准
- •Refuse to participate;
- •Combined hepatocellular-cholangiocarcinoma.
- •Vascular invasion.
- •Extrahepatic metastasis.
- •Lymph node metastasis.
- •Direct extrahepatic invasion.
- •ECOG performance status >1.
研究组 & 干预措施
Group 1
Hepatocellular carcinoma resection
Group 2
Hepatocellular carcinoma transplantation
Group 3
Intrahepatic cholangiocarcinoma resection
Group 4
Intrahepatic cholangiocarcinoma resection+adjuvant treatment
结局指标
主要结局
生存率
次要结局
- 无复发生存率(Detection of intrahepatic recurrence)
- 无合并症生存率
- 手术切缘(After resection)
研究者
研究点 (2)
Loading locations...
相似试验
尚未招募
不适用
An international multicentre observational study to find out whether removing bowel cancer or liver tumors first gives better results in patients who have cancer in both places and need surgery for bothCTRI/2025/07/090078European Federation International Society of Digestive Surgery Coordinating center564
尚未招募
1 期
Affordable Made-in-India Microspheres for Liver Cancer TherapyNCT07436988Post Graduate Institute of Medical Education and Research, Chandigarh18
暂停
2 期
Extended Criteria Treatment for Liver Metastases With Heavy Tumour Burden2024-512397-95-00Oslo University Hospital HF97
尚未招募
不适用
Comparison of safety and technique between portal vein embolization via liver and portal vein embolization via liver performed for liver growth before liver resectionCTRI/2025/09/094450Dr Anu Thakur34
已完成
Unknown
初始不可切除肝癌接受联合治疗后，主要病理学反应与临床病理学的显著性分析：一项回顾性队列研究肝细胞癌ChiCTR220006531160